NYSE: NVSNovartis Ag Stock
$82.80-0.25 (-0.3%)
Updated Sep 22, 2021
NVS Price
$82.80
Fair Value Price
N/A
Market Cap
$185.20B
52 Week Low
$77.04
52 Week High
$98.52
P/E
20.8x
P/B
3.43x
P/S
3.97x
PEG
0.98x
Dividend Yield
4.08%
Revenue
$51.56B
Earnings
$8.98B
Gross Margin
69.1%
Operating Margin
22.77%
Profit Margin
17.4%
Debt to Equity
1.29
Operating Cash Flow
$13B
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
High
Medium
Low
52
Industry average
Reasons for this score
NVS ($82.80) is trading below its intrinsic value of $334.81, according to Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Valuation
NVS is good value based on its earnings relative to its share price (20.8x), compared to the US market average -10.34x)
Valuation
NVS is good value based on its earnings relative to its share price (20.8x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
NVS News
Valuation
NVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
20.8x
Industry
21.92x
Market
-10.34x
NVS is good value based on its earnings relative to its share price (20.8x), compared to the US market average -10.34x)
Valuation
NVS is good value based on its earnings relative to its share price (20.8x), compared to the US Drug Manufacturers - General industry average (21.92x)
Valuation
NVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.43x
Industry
5.12x
NVS is good value based on its book value relative to its share price (3.43x), compared to the US Drug Manufacturers - General industry average (5.12x)
Valuation
NVS price to earnings growth (PEG)
For valuing profitable companies with growth potential
NVS is good value based on it's Price to Earnings and rate of earnings growth, measured by PEG ratio (0.98x)
Valuation
NVS's financial health
Profit margin
Revenue
$13.3B
Net Income
$2.9B
Profit Margin
21.8%
NVS's Earnings (EBIT) of $11.74B can safely cover interest payments on company debt ($35.85B)
Financials
NVS's profit margin has increased (+2.8%) in the last year from (14.6%) to (17.4%)
Financials
Assets to liabilities
Assets
$124.0B
Liabilities
$69.9B
Debt to equity
0.66
NVS's short-term liabilities ($29.63B) exceed its short-term assets ($23.81B)
Financials
NVS's long-term liabilities ($40.25B) exceed its short-term assets ($23.81B)
Financials
NVS's debt has increased relative to shareholder equity (1.29), over the past 5 years ago (0.81)
Financials
NVS's debt to equity ratio (1.29) is considered high
Financials
Cash flow
Operating
$4.1B
Investing
$97.0M
Financing
-$2.9B
NVS's operating cash flow ($13.42B) is sufficient to service the company's debt ($35.85B)
Financials
Novartis Ag Stock FAQ
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.